Septerna 10-Q: Q3 Revenue $18.9M, Net Loss $26.6M, $565.2M Cash Into Mid-2029
SEPN has more than doubled off its 52-week low of $17.55.
Summary
Septerna's Q3 10-Q confirms $18.9M revenue and a $26.6M net loss, with R&D up sharply and $565.2M in cash funding operations into mid-2029. The filing also discloses $61.0M of Q3 ATM sales and a dropped Phase 2b plan for SEP-631.
Key Events · Earnings and Guidance · SEPN
-
Q3 Revenue $18.9M, Net Loss $26.6M
Revenue fell to $18.9M from $21.5M a year earlier, and the quarter swung to a $26.6M net loss from $8.2M of net income in Q3 2025.
-
R&D Spend Steps Up Sharply
Research and development rose to $36.6M from $24.3M, with higher costs across PTH1R, partnered metabolic and other preclinical programs plus $3.0M more payroll.
-
Novo Contract Modification Cuts Revenue
Novo's program substitution triggered a contract modification and a $13.2M cumulative catch-up reduction to revenue in the quarter.
-
Cash of $565.2M Into Mid-2029
Cash, cash equivalents and marketable securities totaled $565.2M at September 30, 2026, which the company says funds operations at least into mid-2029.
Analysis · SEPN · Life Sciences
The headline numbers were already out via the same-day 8-K, but the full 10-Q shows what is actually happening underneath. R&D jumped to $36.6M from $24.3M a year earlier as SEP-479 and SEP-204 move toward the clinic, and a $13.2M cumulative catch-up cut to revenue from the Novo contract modification dragged the top line. Against that, $565.2M of cash and securities funds operations into mid-2029, so there is no near-term financing pressure — and the company raised $61.0M net through the ATM in Q3 at a $39.43 weighted average, well below today's $50.74. The quiet negative is SEP-631: the planned Phase 2b CSU trial is off the table in favor of unspecified signal-finding work.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SEPN was trading at $50.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $17.55 to $51.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.